The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030
Roots Analysis has done a detailed study on Antibody Discovery:Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 450+ pagereport, which features 120+ figures and 140+ tables, please visit this link
Key Market Insights
§ Over 80 companies areoffering antibody discovery services; of these, more than 75 players claim tooffer services related to hit generation.
§ Nearly 180 innovativetechnology platforms have been developed by numerous firms for the purpose ofantibody discovery.
§ Majority ofstakeholders in the competitive market landscape are small / mid-sized firms,catering to the needs of a diverse clientele.
§ In order to get anedge over their competitors in the industry, companies have established theirpresence in different regions across the globe.
§ The rising interest in this field is reflected in the number ofpartnerships inked in the recent past, involving both international andindigenous stakeholders, and focused on antibody discovery for diverse range ofindications.
§ Efforts of theplayers in the field of antibody discovery have garnered significant interestof several venture capital investors.
§ The antibody discovery services market is expected to witness growth ata CAGR of ~10%; the anticipated opportunity is likely to be distributed acrossvarious steps involved in antibody discovery, antibody discovery method, natureof antibody generated and geographies.
§ The market forantibody discovery platforms is currently being driven by the revenues from thelicensing deals; it is anticipated to reach USD 5.9 billion by 2030.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. Structureof Antibodies
3.3. History ofDevelopment
3.4. AntibodyIsotypes
3.5. Mechanismof Action of Antibodies
3.6. Classificationof Antibodies
3.6.1. MonoclonalAntibodies
3.6.2. Polyclonal Antibodies
3.6.3. BispecificAntibodies
3.7. Applicationsof Antibodies
PressRelease: Variation 2 (Format 3)
4. ANTIBODYDISCOVERY PROCESS AND METHODS
4.1. ChapterOverview
4.2. AntibodyDiscovery Process
4.2.1. TargetSelection and Validation
4.2.2. HitGeneration
4.2.3. LeadSelection
4.2.4. LeadOptimization
4.2.4.1. Humanization
4.2.4.2. AffinityMaturation
4.2.4.3. FcEngineering
4.2.5. LeadCharacterization
4.2.6. CandidateSelection
4.3. AntibodyDiscovery Methods
4.3.1. HybridomaMethod
4.3.2. In vitroDisplay Method
4.3.2.1. PhageDisplay
4.3.2.2. YeastDisplay
4.3.2.3. RibosomalDisplay
4.3.3. TransgenicAnimal-Based Method
4.3.4. Single BCell-Based Method
4.3.5. Advantagesand Disadvantages of Existing Antibody Discovery Techniques
4.4. Evolutionof Monoclonal Antibodies
4.4.1. Fully HumanMonoclonal Antibodies
5. ANTIBODYDISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. ChapterOverview
5.2. AntibodyDiscovery Service Providers: List of Industry Players
5.2.1. Analysis byYear of Establishment
5.2.2. Analysis byCompany Size
5.2.3. Analysis byLocation of Headquarters
5.2.4. Analysis byType of Service Offered
5.2.5. Analysis byType of Antibody Discovery Method
5.2.6. GridRepresentation: Analysis by Type of Service Offered, Type of Antibody DiscoveryMethod and Company Size
5.2.7. Analysis byAnimal Model Used
5.2.8. Analysis byType of Antibody Discovered
5.2.9. Analysis byType of Antibody Discovery Method and Type of Antibody Discovered
5.2.10. Analysis byPurpose of Antibody Discovery
5.2.11. Analysis byType of Antibody Discovery Method and Purpose of Antibody Discovery
6. COMPANYCOMPETITIVENESS ANALYSIS
6.1. ChapterOverview
6.2. Methodology
6.3. KeyParameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. AntibodyDiscovery Service Providers based in North America
6.4.2. AntibodyDiscovery Service Providers based in Europe
6.4.3. AntibodyDiscovery Service Providers based in Asia Pacific
7. COMPANYPROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. ChapterOverview
7.2. AntibodyDiscovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. CompanyOverview
PressRelease: Variation 2 (Format 3)
7.2.1.2. AntibodyDiscovery Services
7.2.1.3. RecentDevelopments and Future Outlook
7.2.2. AragenBioscience (A GVK BIO Company)
7.2.2.1. CompanyOverview
7.2.2.2. AntibodyDiscovery Services
7.2.2.3. RecentDevelopments and Future Outlook
7.2.3. DistributedBio
7.2.3.1. CompanyOverview
7.2.3.2. AntibodyDiscovery Services
7.2.3.3. RecentDevelopments and Future Outlook
7.2.4. IntegralMolecular
7.2.4.1. CompanyOverview
7.2.4.2. Antibody DiscoveryServices
7.2.4.3. RecentDevelopments and Future Outlook
7.2.5. LakePharma
7.2.5.1. CompanyOverview
7.2.5.2. AntibodyDiscovery Services
7.2.5.3. RecentDevelopments and Future Outlook
7.3. AntibodyDiscovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. CompanyOverview
7.3.1.2. FinancialInformation
7.3.1.3. AntibodyDiscovery Services
7.3.1.4. RecentDevelopments and Future Outlook
7.3.2. ImmunoPrecise Antibodies
7.3.2.1. CompanyOverview
7.3.2.2. FinancialInformation
7.3.2.3. AntibodyDiscovery Services
7.3.2.4. RecentDevelopments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. CompanyOverview
7.3.3.2. AntibodyDiscovery Services
7.3.3.3. RecentDevelopments and Future Outlook
7.4. AntibodyDiscovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. CompanyOverview
7.4.1.2. AntibodyDiscovery Services
7.4.1.3. RecentDevelopments and Future Outlook
7.4.2. VivaBiotech
7.4.2.1. CompanyOverview
7.4.2.2. FinancialInformation
7.4.2.3. AntibodyDiscovery Services
7.4.2.4. RecentDevelopments and Future Outlook
7.4.3. WuXiBiologics
7.4.3.1. CompanyOverview
7.4.3.2. FinancialInformation
PressRelease: Variation 2 (Format 3)
7.4.3.3. AntibodyDiscovery Services
7.4.3.4. RecentDevelopments and Future Outlook
8. ANTIBODYDISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. ChapterOverview
8.2. AntibodyDiscovery Platform Providers: List of Industry Players
8.2.1. Analysis byYear of Establishment
8.2.2. Analysis byCompany Size
8.2.3. Analysis byLocation of Headquarters
8.2.4. Analysis byType of Antibody Discovered
8.3. AntibodyDiscovery: List of Technologies and Platforms
8.3.1. Analysis byType of Antibody Discovery Method
8.3.2. Analysis byType of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis byAnimal Model Used
8.3.4. Analysis byPatent Availability
9. TECHNOLOGYCOMPETITIVENESS ANALYSIS
9.1. ChapterOverview
9.2. Methodology
9.3. KeyParameters
9.4. TechnologyCompetitiveness Analysis: Antibody Discovery Platforms
9.4.1. Competitiveness Analysis: Library Based Antibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other Antibody Discovery Platforms
10. COMPANYPROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. ChapterOverview
10.2. ImmunoPrecise Antibodies
10.2.1. CompanyOverview
10.2.2. FinancialInformation
10.2.3. Portfolio ofAntibody Discovery Platforms
10.2.3.1. Abthena™
10.2.3.2. B cell Select™
10.2.3.3. DeepDisplay™
10.2.3.4. ModiFuse™
10.2.3.5. ModiPhage™
10.2.3.6. ModiSelect™
10.2.3.7. ModiTune™
10.2.4. Recent Developments and Future Outlook
10.3. HarbourBioMed
10.3.1. CompanyOverview
10.3.2. Portfolio ofAntibody Discovery Platforms
10.3.2.1. H2L2 Platform
10.3.2.2. HCAb Platform
10.3.3. Recent Developments and Future Outlook
10.4. Kymab
10.4.1. CompanyOverview
10.4.2. Portfolio ofAntibody Discovery Platforms
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook
10.5. LigandPharmaceuticals
PressRelease: Variation 2 (Format 3)
10.5.1. CompanyOverview
10.5.2. FinancialInformation
10.5.3. Portfolio ofAntibody Discovery Platforms
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developmentsand Future Outlook
10.6. MorphoSys
10.6.1. CompanyOverview
10.6.2. FinancialInformation
10.6.3. Portfolio ofAntibody Discovery Platforms
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. RecentDevelopments and Future Outlook
11. REGIONALCAPABILITY ANALYSIS
11.1. ChapterOverview
11.2. KeyAssumptions and Methodology
11.3. RegionalCapability Analysis: Antibody Discovery Service Providers
11.3.1. RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin North America
11.3.2. RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin Europe
11.3.3. RegionalCapability Analysis: Distribution of Antibody Discovery Service Providers basedin Asia-Pacific
11.4. RegionalCapability Analysis: Antibody Discovery Platform Providers
11.4.1. RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in North America
11.4.2. RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in Europe
11.4.3. RegionalCapability Analysis: Distribution of Antibody Discovery Platform Providersbased in Asia-Pacific
11.5. ConcludingRemarks
12. PARTNERSHIPSAND COLLABORATIONS
12.1. ChapterOverview
12.2. PartnershipModels
12.3. List ofPartnerships and Collaborations
12.3.1. Analysis byYear of Partnership
12.3.2. Analysis byType of Partnership
12.3.3. Analysis bythe Type of Company (Service / Platform Providers)
12.3.4. Analysis byType of Antibody Discovered
12.3.5. Analysis byYear of Partnership and Type of Partner
12.3.6. Analysis byType of Partnership and Type of Partner
12.3.7. Most ActivePlayers: Analysis by Number of Partnerships
12.3.8. Most PopularTechnologies: Analysis by Number of Partnerships
12.3.9. RegionalAnalysis
12.3.9.1. Intercontinental and Intracontinental Agreements
PressRelease: Variation 2 (Format 3)
13. FUNDINGAND INVESTMENT ANALYSIS
13.1. ChapterOverview
13.2. Types ofFunding
13.3. AntibodyDiscovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis byNumber of Instances
13.3.2. Analysis byAmount Invested
13.3.3. Analysis byType of Funding
13.3.4. Most ActivePlayers: Analysis by Amount Invested
13.3.5. Most ActiveInvestors: Analysis by Number of Funding Instances
13.3.6. RegionalAnalysis by Amount Invested
13.4. ConcludingRemarks
14. ANTIBODYDISCOVERY SERVICES: MARKET FORECAST
14.1. ChapterOverview
14.2. ForecastMethodology
14.3. GlobalAntibody Discovery Services Market, 2020-2030
14.4. GlobalAntibody Discovery Services Market: Distribution by Steps Involved in AntibodyDiscovery Process, 2020-2030
14.4.1. AntibodyDiscovery Services Market for Antigen Designing, 2020-2030
14.4.2. AntibodyDiscovery Services Market for Hit Generation, 2020-2030
14.4.3. AntibodyDiscovery Services Market for Lead Selection, 2020-2030
14.4.4. AntibodyDiscovery Services Market for Lead Optimization, 2020-2030
14.4.5. AntibodyDiscovery Services Market for Lead Characterization, 2020-2030
14.5. GlobalAntibody Discovery Services Market: Distribution by Antibody Discovery Method,2020-2030
14.5.1. AntibodyDiscovery Services Market for Phage Display, 2020-2030
14.5.2. AntibodyDiscovery Services Market for Yeast Display, 2020-2030
14.5.3. Antibody DiscoveryServices Market for Hybridoma Method, 2020-2030
14.5.4. AntibodyDiscovery Services Market for Transgenic Animal Based Method, 2020-2030
14.5.5. AntibodyDiscovery Services Market for Single Cell Based Method, 2020-2030
14.5.6. AntibodyDiscovery Services Market for Other Methods, 2020-2030
14.6. GlobalAntibody Discovery Services Market: Distribution by Nature of AntibodyGenerated, 2020-2030
14.6.1. AntibodyDiscovery Services Market for Humanized Antibodies, 2020-2030
14.6.2. AntibodyDiscovery Services Market for Human Antibodies, 2020-2030
14.6.3. AntibodyDiscovery Services Market for Chimeric Antibodies, 2020-2030
14.6.4. AntibodyDiscovery Services Market for Murine Antibodies, 2020-2030
14.7. GlobalAntibody Discovery Services Market: Distribution by Region, 2020-2030
14.7.1. AntibodyDiscovery Services Market in North America, 2020-2030
14.7.2. AntibodyDiscovery Services Market in Europe, 2020-2030
14.7.3. AntibodyDiscovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
14.7.4. AntibodyDiscovery Services: Market Attractiveness Analysis by Region
15. ANTIBODYDISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. ChapterOverview
15.2. KeyAssumptions
15.3. ForecastMethodology
15.4. GlobalAntibody Discovery Platforms Market, 2020-2030
15.5. GlobalAntibody Discovery Platforms Market: Distribution by Region, 2020-2030
15.5.1. AntibodyDiscovery Platforms Market in North America, 2020-2030
15.5.2. AntibodyDiscovery Platforms Market in Europe, 2020-2030
15.5.3. AntibodyDiscovery Platforms Market in Asia-Pacific, 2020-2030
16. CASE INPOINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
16.1. ChapterOverview
PressRelease: Variation 2 (Format 3)
16.2. Humira®(Adalimumab)
16.2.1. DrugOverview
16.2.2. DiscoveryProcess and Method
16.2.3. HistoricalSales
16.3. Keytruda®(Pembrolizumab)
16.3.1. DrugOverview
16.3.2. DiscoveryProcess and Method
16.3.3. HistoricalSales
16.4. Herceptin®(Trastuzumab)
16.4.1. DrugOverview
16.4.2. DiscoveryProcess and Method
16.4.3. HistoricalSales
16.5. Avastin®(Bevacizumab)
16.5.1. DrugOverview
16.5.2. DiscoveryProcess and Method
16.5.3. HistoricalSales
16.6. Rituxan®(Rituximab)
16.6.1. DrugOverview
16.6.2. DiscoveryProcess and Method
16.6.3. HistoricalSales
17. CASESTUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
17.1. Importanceof Antibody Humanization and Affinity Maturation
17.2. AntibodyHumanization and Affinity Maturation Service and Platform Providers: MarketLandscape
17.3. AntibodyHumanization: Publication Analysis
17.3.1. PublicationAnalysis: Year-Wise Trend
17.3.2. PublicationAnalysis: Key Journals
17.3.3. PublicationAnalysis: Distribution by Animal Model Used
17.3.4. PublicationAnalysis: Distribution by Method Used for Humanization
17.4. AntibodyHumanization Service and Platform Providers: SWOT Analysis
18. FUTUREGROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
18.1. ChapterOverview
18.2. AnticipatedShift from Monoclonal Antibodies to Other Novel Formats
18.3. Technological Advancements to Overhaul Conventional Antibody DiscoveryProcesses
18.4. Transitionto CADD-based Approaches to Help Achieve Better Operational Efficiencies
18.5. RisingDemand for Antibody-based Treatment Options across Non-Oncology Indications
18.6. GrowingMarket Opportunities in the Asia-Pacific Region
18.7. ExpectedIncrease in Number of Collaborations and Licensing Activity
18.8. ConcludingRemarks
19. EXECUTIVEINSIGHTS
19.1. ChapterOverview
19.2. AbverisAntibody
19.2.1. CompanySnapshot
19.2.2. TraceyMullen, Chief Executive Officer (Q2 2020)
19.3. NidusBiosciences
19.3.1. CompanySnapshot
19.3.2. LisaDelouise, Founder and Chief Technology Officer (Q1 2020)
PressRelease: Variation 2 (Format 3)
19.4. AvantGen
19.4.1. CompanySnapshot
19.4.2. Mark Kubik,Chief Business Officer (Q1 2020)
19.5. Single CellTechnology
19.5.1. CompanySnapshot
19.5.2. Chun-NanChen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
19.6. DistributedBio
19.6.1. CompanySnapshot
19.6.2. Giles Day,Co-Founder and Chief Executive Officer (Q2 2018)
19.7. AbCellera
19.7.1. CompanySnapshot
19.7.2. KevinHeyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
19.8. AbGenicsLife Sciences
19.8.1. CompanySnapshot
19.8.2. Sanjiban KBanerjee, Director (Q2 2018)
19.9. CDILaboratories
19.9.1. CompanySnapshot
19.9.2. IgnacioPino, Chief Executive Officer and President (Q2 2017)
19.10. APBiosciences
19.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
19.11. YUMAB
19.11.1. Company Snapshot
19.11.2. Thomas Schirrmann, Chief Executive Officer and GeneralManager (Q2 2017)
19.12. AntibodySolutions
19.12.1. Company Snapshot
19.12.2. Debra Valsamis, Business Development Associate (Q22017)
19.13. LigandPharmaceuticals
19.13.1. Company Snapshot
19.13.2. Christel Iffland, Vice President (Q2 2017)
19.14. LakePharma
19.14.1. Company Snapshot
19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)
20. CONCLUDINGREMARKS
20.1. ChapterOverview
20.2. KeyTakeaways
21. APPENDIX1: TABULATED DATA
22. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
